Pledge Your Birthday …Select Nonprofit and choose AIM at Melanoma. Add a cover photo and fill in the fundraiser details. Click Create. Your…
Volunteer Get Involved With AIM AIM at Melanoma is always looking for dedicated and energetic volunteers to engage in our mission…
Tanning Legislation in 2019 …tanning devices. Source: AIM at Melanoma, StateNet, and NCSL, 2006-2008 Note: List may not be comprehensive but is representative of the state…
Is a Clinical Trial is Right for You Your doctor may tell you about a trial melanoma that might be suitable for you. Or you might find…
Colorado [aim_melanoma_specialist] Find a Specialist University of Colorado Cancer Center Anschutz Cancer Pavilion * Cutaneous Oncology Dept. 1665 Aurora Court Aurora,…
Delaware [aim_melanoma_specialist] Find a Specialist Helen Graham Cancer Center Regional Hematolgoy/Onc, P.A. 4701 Ogletown-Stanton Rd., Ste 2400 Newark, DE 19713 302-731-7782…
District of Columbia [aim_melanoma_specialist] Find a Specialist Lombardi Comprehensive Cancer Center * Medstar Georgetown University Hospital 3800 Reservoir Road, NW. Washington, DC 20007 202-444-7404…
Florida [aim_melanoma_specialist] Find a Specialist Mayo Clinic * 4500 San Pablo Road Jacksonville, FL 32224 904-953-2272 mayoclinic.org Roxana Dronca, MD Winston…
Hawaii [aim_melanoma_specialist] Unfortunately, we have no specialists listed for this state. Please check your closest neighboring state for a list of…
Idaho [aim_melanoma_specialist] Find a Specialist St. Luke’s 100 E Idaho St. Boise ID, 83712 208-381-2748 www.stlukesonline.org Norman Zuckerman, MD Gem State…
Jun. 09, 2026 The FDA Just Approved a New Sunscreen Ingredient— What It Means for Patients with Skin Cancer, Survivors, and the General Public
Jun. 05, 2026 Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026 Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026 Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors